Pritesh Shah, Chief Commercial Officer at NovoCure Ltd (NVCR), sold 11,086 shares at $74.50 ($804K) on 2022-03-03, disclosed to the SEC on 2022-03-07.
Seasonal sale ($804k) by Chief Commercial Officer — this insider has traded NVCR in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.50 | 997 | $74K | 9.2% |
| 2 | $74.50 | 997 | $74K | 9.2% |
| 3 | $70.41 | 1,914 | $135K | 16.8% |
| 4 | $70.41 | 1,914 | $135K | 16.8% |
| 5 | $73.34 | 2,632 | $193K | 24.0% |
| 6 | $73.34 | 2,632 |
| $193K |
| 24.0% |
| Total | $72.54 avg | 11,086 | $804K | 100% |
| Filing → |
| NVCR | SELL | 2023-03-07 | $3.3M | — | Filing → |
| NVCR | SELL | 2023-03-06 | $141K | — | Filing → |
| NVCR | SELL | 2023-03-02 | $294K | — | Filing → |